Inhibikase Therapeutics, Inc. Share Price

Inhibikase Therapeutics, Inc. Share Price

NASDAQ: IKT | Micro Cap
$1.55
-$0.13 (-7.46%) Last updated on 31 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Inhibikase Therapeutics, Inc. Stock Performance

Open
$1.67
Prev. Close
$1.68
Circuit Range
N/A
Day Range
$1.52 - $1.67
Year Range
$1.33 - $2.61
Volume
60,996
Average Traded
$1.57

Inhibikase Therapeutics, Inc. Share Price Today

As of 31 October 2026, Inhibikase Therapeutics, Inc.'s share price is $1.55. The stock opened at $1.67, compared to its previous close of $1.68. During today's trading session, Inhibikase Therapeutics, Inc.'s share price traded between $1.52 and $1.67, with an average price of $1.59. Over the past 52 weeks, the stock has recorded a high of $2.61 and a low of $1.33. In terms of performance, Inhibikase Therapeutics, Inc.'s share price has declined by 17.99% over the last six months and is up 4.73% on a year-on-year basis.

Inhibikase Therapeutics, Inc. Share Price Chart

Line chart of the Inhibikase Therapeutics, Inc. price trend over the selected period. The price fell overall, ranging from 1.53 to 1.67, ending at 1.55.
$1.52$1.67
L
Show Current Price
H

Inhibikase Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$152.38M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.43
Revenue (TTM)
$0.00
Return On Equity (TTM)
-39.55%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-64.21%

Inhibikase Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$11.93-$12.73-$16.38-$19.59
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-6.71%-28.67%-19.60%

Inhibikase Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.12$0.26$0.00$0.00
Net Profit-$18.05-$19.03-$27.52-$48.26
Net Profit Margin-15041.67%-7319.23%N/AN/A
Income ChangeN/A-5.43%-44.61%-75.36%

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Inhibikase Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$2.05
$1.55
-24.76%
Sep 2026
$2.35
$2.06
-16.94%
Aug 2026
$2.23
$2.48
+13.76%
Jul 2026
$2.04
$2.18
+7.44%
Jun 2026
$1.77
$2.03
+16.61%
May 2026
$1.87
$1.74
-7.94%
Apr 2026
$1.71
$1.89
+13.17%
Mar 2026
$1.94
$1.67
-18.54%
Feb 2026
$1.57
$2.05
+36.67%
Jan 2026
$2.04
$1.50
-27.18%
Dec 2025
$1.53
$2.06
+33.33%
Nov 2025
$1.34
$1.54
+4.39%

IKT Share Price FAQs